GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioventus Inc (NAS:BVS) » Definitions » Price-to-Owner-Earnings

Bioventus (Bioventus) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bioventus Price-to-Owner-Earnings?

As of today (2024-06-06), Bioventus's share price is $6.80. Bioventus does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Bioventus's Price-to-Owner-Earnings or its related term are showing as below:

During the past 9 years, the highest Price-to-Owner-Earnings of Bioventus was 41.38. The lowest was 9.06. And the median was 35.14.


BVS's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), Bioventus's share price is $6.80. Bioventus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.34. Therefore, Bioventus's PE Ratio for today is At Loss.

As of today (2024-06-06), Bioventus's share price is $6.80. Bioventus's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.27. Therefore, Bioventus's PE Ratio without NRI for today is At Loss.

During the past 9 years, Bioventus's highest PE Ratio without NRI was 62.70. The lowest was 0.00. And the median was 19.92.


Bioventus Price-to-Owner-Earnings Historical Data

The historical data trend for Bioventus's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventus Price-to-Owner-Earnings Chart

Bioventus Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - - 40.93 - -

Bioventus Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioventus's Price-to-Owner-Earnings

For the Medical Devices subindustry, Bioventus's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioventus's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bioventus's Price-to-Owner-Earnings falls into.



Bioventus Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bioventus's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.80/-0.12
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventus  (NAS:BVS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Bioventus Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Bioventus's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventus (Bioventus) Business Description

Traded in Other Exchanges
N/A
Address
4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in U.S and International markets.
Executives
Bihl Anthony P Iii director, officer: Interim CEO 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
John A. Bartholdson director, 10 percent owner C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Juniper Investment Company, Llc 10 percent owner 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315
Katrina J Church officer: SVP & Chief Compliance Officer 3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303
Alexis P Michas 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Juniper Targeted Opportunities, Lp 10 percent owner 555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022
Juniper Targeted Opportunity Fund, L.p. 10 percent owner 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Mark Leonard Singleton officer: SEE REMARKS C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Anthony D'adamio officer: SVP & General Counsel C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Kenneth Michael Reali director, officer: Chief Executive Officer 5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613
John Nosenzo officer: Chief Commercial Officer C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Alessandra Pavesio officer: SVP & Chief Science Officer C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gregory O. Anglum officer: SVP and CFO C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703